PCSK9 Forum
August 2014
Facebook Twitter RSS
For latest updates
Register today
Home About PCSK9 Forum News Expert Opinion Education & Resources Register
PCSK9 Education and Research Forum: Newsletter - August 2014

Looking to ESC Congress 2014: what will be hot for PCSK9 Research?

ESC discusses innovations in lipid-lowering therapy: PCSK9 features high on the list
Focus on heterozygous FH: who are these patients and why do they matter?
New frontiers for the high-risk patient
And much more… Join PCSK9 Forum for the latest live coverage

From the Editors

Implementing Models of Care in FH – the real challenge ahead
Prof. Gerald F. Watts, Perth, Australia makes the case

Hot Topics

IMPROVE-IT: Will it prove anything?
Prof. Anthony S. Wierzbicki, London, UK adds to debate

Send an invitation to join PCSK9 Forum to your colleagues, click here for the invite link

Our mission

Our goal

The PCSK9 Education and Research Forum is the major, globally-recognised resource of independent, scientific knowledge of the critical importance of PCSK9 inhibition in the search for treatments which promise to transform the prognosis of millions of people with hypercholesterolaemia and accelerated atherosclerotic vascular disease.

Our response to this challenge

Established by leading researchers as a not-for-profit organisation, the PCSK9 Education and Research Forum will provide healthcare professionals with open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; and, an extensive library of accredited educational materials tailored to the differing needs of a spectrum of audiences. As a result, the Forum will expand awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Our partnership and outreach

Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum will reach out to academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum will establish educational partnerships with such organisations through jointly sponsored symposia as well as accredited research and educational programmes.
About PCSK9 Education and Research Forum

Watch the Aims & Objectives video
Read our Mission Statement
Partnership and outreach
Meet our Editorial Board
View Forthcoming Meetings

“Lower is better” for LDL – a new meta-analysis
Is the ABCC6 gene important for cholesterol metabolism?
Understanding the role of PCSK9 in dyslipidaemia

Read more news »
Hot topics

Video: Lowering LDL-C: How low and for how long?
Dr Evan Stein
Video: LDL-C: how low should clinicians aim for?
Prof Henry Ginsberg

'Lower is better' for LDL, a new meta-analysis. 'How low should we go' - a key question in dyslipidaemia management
http://www.ncbi.nlm.nih.gov/ pubmed/25082583

Is the #ABCC6 gene important for cholesterol metabolism? #PCSK9
http://www.ncbi.nlm.nih.gov/ pubmed/25064003

Understanding the role of #PCSK9 in dyslipidaemia. Potential of PCSK9 inhibition against coronary heart disease
http://www.ncbi.nlm.nih.gov/ pubmed/25070550

  Supported by educational grants from: Amgen Lilly pFizer Sanofi  
Copyright PCSK9 Forum 2014. Please click here to unsubscribe from future mailings.